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Abstract
Background: Data on survival and prognosis factors in incident cohorts are scarce in systemic sclerosis (SStc). To
describe survival, standardized mortality ratio (SMR), and prognosis factors in systemic sclerosis (SSc), we analyzed
a multicenter French cohort of incident patients and performed a systematic review of the literature and
meta-analysis.
Methods: A multicenter, French cohort study was conducted between January 1, 2000, and December 31, 2013. Patients
were followed-up until July 1, 2016.
A systematic review of the literature was carried out in MEDLINE and EMBASE up to July 2017. Meta-analysis was
performed using all available data on SMR and hazard ratios of prognosis factors.
Results: A total of 625 patients (493 females, 446 lcSSc) were included. During the study period, 104 deaths (16.6%) were
recorded and 133 patients were lost to follow-up. Overall survival rates at 1, 3, 5, and 10 years from diagnosis were 98.0%,
92.5%, 85.9%, and 71.7% respectively in the French cohort. Overall SMR was 5.73 (95% CI 4.68–6.94). Age at diagnosis > 60
years, diffuse cutaneous SSc, scleroderma renal crisis, dyspnea, 6-min walking distance (6MWD), forced vital capacity
< 70%, diffusing capacity of the lungs for carbon monoxide < 70%, pulmonary hypertension (PH), telangiectasia, valvular
disease, malignancy, anemia, and CRP > 8mg/l were associated with a poorer survival after adjustment.
Eighteen studies (11,719 patients) were included in the SMR meta-analysis and 36 studies (26,187 patients) in the
prognosis factor analysis. Pooled SMR was 3.45 (95%CI 3.03–3.94). Age at disease onset, male sex, African origin, diffuse
cutaneous SSc, anti-Scl70 antibodies, cardiac and renal involvement, interstitial lung disease, PH, and malignancy were
significantly associated with a worse prognosis. Anti-centromere antibodies were associated with a better survival.
Conclusions: Overall, our study highlights a high mortality rate in SSc patients and confirms previously described
prognosis factors related to skin extension and organ involvement while identifying additional prognosis factors such
as autoantibody status, telangiectasia, 6MWD, and valvular disease.
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Background
Systemic sclerosis (SSc) is an autoimmune disease, charac-
terized by microvascular damage, dysregulation of both
innate and adaptative immunity, and fibrosis of multiple
organs. The causes of SSc-related deaths evolved over the
last decades, with cardiac and respiratory complications
currently being the leading causes of death [1, 2].
Prior cohort studies comparing contemporary and his-
torical cohort have suggested an improvement of survival
rates over time [1, 3, 4]. Yet, two recent meta-analyses
have reported that standardized mortality ratio (SMR) was
stable over time [5, 6]. Moreover, most of the observa-
tional studies investigating mortality in SSc included
prevalent cases, which may result in an underestimation
of mortality due to a survivor bias. Data on survival in in-
cident cohorts are scarce in SSc [7–12].
Previous studies [7, 13–26] reported risk factors for poor
survival in SSc such as male sex, diffuse cutaneous subtype,
and specific organ involvement. Recently, Elhai et al. devel-
oped a prognostic score from the large EUSTAR database,
which accurately predicts 3-year mortality [2]. To our
knowledge, two meta-analyses combined the results of the
available literature to assess prognosis factors [5, 27]. How-
ever, these meta-analyses did not assess prognosis factors
such as auto-antibody profile, genetic background, and can-
cer and did not assess the influence of prevalent versus inci-
dent cases.
The aim of the present study was to fill these gaps by
assessing survival and prognosis factors in a multicenter
French cohort of incident SSc patients and by performing
a systematic review of the literature and meta-analysis in-
cluding all available prognosis factors and SMR.
Methods
Population
The French National Scleroderma Cohort includes 42
centers. The present analysis was restricted to five uni-
versity hospitals, Lille, Paris (two centers), Nantes, and
Lyon to ensure better quality of data, especially on sur-
vival data. These five centers participated in recruiting
about two thirds of the National Cohort. Data were
retrospectively collected before 2010 and then prospect-
ively collected.
Patients were included between January 1, 2000, and
December 31, 2013, if they met the following inclusion
criteria: (i) be aged over 18, (ii) fulfill the ACR 1980 pre-
liminary classification criteria [28] or ACR/EULAR 2013
classification criteria [29] for SSc, (iii) have at least one
additional visit after the inclusion visit, and (iv) be inci-
dent cases, defined as patients having disease duration
from time of diagnosis to enrolment in the study of less
than 3 years. Patients were followed-up until July 1,
2016. Patients were considered as lost to follow-up if the
vital status could not be ascertained. When possible, the
vital status was ascertained by querying death registers
at birth town councils.
Collected data and variable definition
Data collected at the inclusion visit were patient demo-
graphics, history of Raynaud phenomenon (RP) and first
non-RP symptom, SSc subtype and modified Rodnan
skin score (mRSS), auto-antibody profile, and organ
involvement.
Disease onset was defined as the time of onset of first
non-RP symptom. Interstitial lung disease was diagnosed
on HRCT or chest x-ray. Pulmonary function tests includ-
ing forced vital capacity (FVC) and diffusing capacity of the
lungs for carbon monoxide (DLCO) were collected.
Six-minute walking distance (6MWD) was collected. Pul-
monary hypertension (PH) was suspected on a Doppler
echocardiogram when systolic pulmonary arterial pressure
(PAP) was estimated to be > 35mmHg or maximum tricus-
pid regurgitant jet velocity > 2.8m/s. Pulmonary arterial
hypertension (PAH) was confirmed by right heart
catheterization (RHC) when mean PAP was found to be ≥
25mmHg at rest, with mean pulmonary arterial wedge
pressure ≤ 15mmHg. EKG alterations, left ventricular ejec-
tion fraction (LVEF), diastolic dysfunction [30], valvular dis-
ease (excluding tricuspid valve regurgitation to avoid
confounding with PH), and pericarditis were recorded ac-
cording to the American Society of Echocardiography and
European Association of Cardiovascular Imaging guidelines
[30]. Scleroderma renal crisis was defined as new onset
hypertension > 150/85mmHg associated with a decrease in
renal function or manifestations of malignant hypertension.
Gastrointestinal tract involvement included reflux, dysmoti-
lity, constipation, or diarrhea; signs of bacterial overgrowth
and/or malabsorption; and abnormal manometry and/or
endoscopy test. Muscle involvement included myalgia and/
or muscle weakness and/or elevation of creatinine kinase
(CPK). Joint involvement included arthralgia, synovitis,
and/or tendon friction rubs. Anemia was defined as a
hemoglobin level < 12 g/dl. Smoking included self-reported
current or former cigarette smoking.
Systematic review and meta-analysis
The meta-analysis was conducted according to MOOSE
guidelines [31]. MEDLINE and EMBASE databases were
queried by two of the authors (MRP and DL) using the
following search terms: ((systemic sclerosis [Title]) OR
(scleroderma, systemic[Title])) AND ((death) OR (mor-
tality) OR (prognosis) OR (survival)). Cochrane did not
retrieve additional abstracts. All records published be-
fore July 1, 2017, were included in the search. Language
was restricted to English or French. Reference list of se-
lected studies was hand-searched for additional relevant
studies to be included in the meta-analysis.
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Two of the authors (MRP and DL) independently
screened the titles and abstracts of the retrieved records
to identify eligible articles. The full text of eligible arti-
cles was read for inclusion in the meta-analysis. Selected
articles were compared, and in case of disagreement, de-
cisions were made by consensus.
Cohort studies of unselected adult SSc patients asses-
sing routine clinical and laboratory prognosis factors and
SMR were included. Studies which included patients diag-
nosed with SSc overlap with other connective tissue dis-
eases were excluded.
Studies from the same centers were included if their
respective study periods were different. If, for the same
center, two studies covered an overlapping study period,
data from the largest cohort were kept in the analysis. A
study was recorded as an incident according to the au-
thors’ definition.
Quality of the studies was assessed using the Newcastle-
Ottawa scale [32].
Data were extracted and entered into a predefined
spreadsheet table which included the following items:
study design, length of follow-up, definition of disease
onset, disease duration, SMR, and adjusted or, if unavail-
able, unadjusted hazard ratios (HR) for each studied
prognosis factor.
Data analysis
Characteristics of the population were described using
mean ± standard deviation or median (interquartile range
(IQR)) in case of non-normality, for quantitative variables,
and number (percentage) for qualitative variables. Compari-
sons between limited cutaneous SSc (lcSSc) and diffuse cu-
taneous SSc (dcSSc) patients were conducted using the
Student t test or Wilcoxon test in case of non-normality for
quantitative variables and Fisher’s exact test for qualitative
variables.
Survival was estimated from diagnosis using the
Kaplan-Meier method. Prognosis factors were assessed
by Cox regression analysis in the non-adjusted analysis
and subsequently adjusted for age, sex, and SSc subtype.
The assumption that hazard ratios were constant over
time was verified. SMR was calculated as the ratio of ob-
served death in the cohort to the number of death of the
French age/sex-matched population in 2014.
We calculated weighted pooled summary estimates of
SMR and HR of prognosis factors. For each meta-analysis,
we used the DerSimonian and Laird method. Accordingly,
studies were considered to be a random sample from a
population of studies. Heterogeneity was assessed using
an I2 statistic and a chi-square heterogeneity statistic. A
random-effects model was used to combine data. The
overall effect was estimated using a weighted average
of individual effects, with weights inversely propor-
tional to variance in observed effects. Publication bias
was evaluated with a funnel plot and Egger’s test. The
pooled SMR and HR were estimated with 95% confi-
dence interval (CI). Meta-regression was used to as-
sess the impact of mid-cohort year, the proportion of
males, the proportion of diffuse cutaneous forms, and
the prevalence of anti-Scl70 antibodies on SMR. The
impact of diagnosis of PH by RHC on the association
of PH with mortality was evaluated. Separate analyses
were performed for (i) SMR according to whether a
given study included incident cases only and (ii) HR
of PH diagnosed by either echocardiography and/or
RHC and PH diagnosed by RHC.
All analyses were performed using R software with
the survival and metafor packages. p values less than
0.05 were considered significant.
Results
French cohort study
Baseline characteristics
A total of 625 patients (493 females, 446 lcSSc) were in-
cluded. Mean age at disease onset was 52.7 ± 14.9 years.
The median disease duration from disease onset was 0.8
(IQR 2.2) years. Median follow-up time was 4.4 (IQR
5.3) years. The baseline characteristics are shown in
Table 1.
Survival and standardized mortality ratio
During the study period, 104 deaths (16.6%) were re-
corded and 133 patients were lost to follow-up. Overall
survival rates at 1, 3, 5, 10, and 15 years from diagnosis
were 98.0% (95% CI 96.9–99.1%), 92.5% (90.4–94.7%),
85.9% (82.8–89.1%), 71.7% (66.3–77.5%), and 53% (33.8–
83.4%) respectively. Survival rates for the diffuse and
limited cutaneous subtypes are shown in Fig. 1 and in
Additional file 1: Table S1. Overall SMR was 5.73 (95%
CI 4.68–6.94).
Prognosis factors
Age of diagnosis > 60 years, dcSSc subtype, telangiecta-
sia, scleroderma renal crisis, severe dyspnea NYHA
functional classes III and IV, a shorter distance at the
6MWD, FVC < 70%, DLCO < 70%, PH, valvular disease,
anemia, CRP > 8mg/l, and cancer were associated with a
worse prognosis (Table 2).
No association was found for digital ulcers, gastro-
intestinal, articular, muscular involvement, and specific
auto-antibodies after adjustment.
Male sex showed a trend towards worse outcome, but
without reaching statistical significance (HR = 1.53; 95%
CI 0.98–2.39; p = 0.06).
Meta-analysis: study selection
A total of 4128 citations were assessed for inclusion.
After screening, 244 abstracts were deemed potentially
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Table 1 Demographics and clinical characteristics of 625 patients with SSc at baseline
N (N for dcSSc) Total dcSSc lcSSc p
Demographics
Female sex 625/179 493 (79) 124 (69) 369 (83) < 0.001
Age at first RP (years) 554/155 45.4 ± 15.7 45.8 ± 15.7 45.3 ± 15.8 0.736
Age at first non-RP symptom (years) 502/160 50.6 ± 14.5 48.5 ± 14.4 51.5 ± 14.4 0.031
Age at diagnosis (years) 625/179 52.7 ± 14.9 49.5 ± 14.5 53.9 ± 14.9 < 0.001
Disease duration from first non-RP symptom to diagnosis (years) 499/160 0.8 [2.2] 0.7 [1.4] 0.9 [2.7] 0.042
Follow-up time from inclusion to death or last visit (years) 625/179 4.4 [5.3] 4.0 [5.2] 4.8 [5.3] 0.023
Genetic background
European 503/147 453 (90) 118 (80) 335 (94) < 0.001
African 503/147 50 (10) 29 (20) 21 (6) < 0.001
Skin involvement
lcSSc 625/179 446 (71) – –
mRSS 342/123 9.2 ± 10.2 19.6 ± 10.1 3.5 ± 3.6 < 0.001
Telangiectasia 572/160 264 (46) 65 (41) 199 (48) 0.112
Calcinosis 549/152 64 (12) 7 (5) 57 (14) < 0.001
Digital ulcers (past or active) 538/145 161 (30) 66 (46) 95 (24) < 0.001
Pulmonary involvement
NYHA 0.702
Classes I–II 515/150 425 (83) 122 (81) 303 (83)
Classes III–IV 515/150 90 (17) 28 (19) 62 (17)
6MWD (meters) 274/61 427 ± 127 432 ± 135 425 ± 125 0.705
TLC < 70% predicted 472/145 64 (14) 33 (23) 31 (9) < 0.001
FVC < 70% predicted 475/148 82 (17) 44 (30) 38 (12) < 0.001
DLCO < 70% predicted 471/141 249 (53) 102 (72) 147 (45) < 0.001
Interstitial lung disease 582/166 262 (45) 115 (69) 147 (35) < 0.001
PH (echo. and/or RHC) 547/157 67 (12) 18 (11) 49 (13) 0.775
sPAP (echo.) 0.004
< 35 mmHg 397/118 307 (77) 89 (75) 218 (78)
35–46 mmHg 397/118 43 (11) 21 (18) 22 (8)
> 46 mmHg 397/118 47 (12) 8 (7) 39 (14)
PAH (RHC) 490/116 40 (8) 4 (3) 36 (10) 0.033
Heart involvement
Arrhythmia 519/150 17 (3) 5 (3) 12 (3) 1.000
AV block 512/146 7 (1) 4 (3) 3 (1) 0.106
BB block 479/128 16 (3) 6 (5) 10 (3) 0.388
LVEF (%) 402/102 64.9 ± 7.1 65.5 ± 8.6 64.7 ± 6.6 0.251
Diastolic dysfunction 423/110 20 (5) 6 (5) 14 (4) 0.613
Pericarditis 478/136 32 (7) 14 (10) 18 (5) 0.066
Valvular disease 430/111 29 (7) 5 (5) 24 (8) 0.380
Renal involvement
GFR < 80 ml/min 459/136 179 (39) 38 (28) 141 (44) 0.002
Scleroderma renal crisis 428/139 44 (10) 31 (22) 13 (5) < 0.001
Gastrointestinal involvement 611/172 429 (70) 135 (78) 294 (67) 0.006
BMI (kg/m2) 514/159 24.4 ± 5.0 23.6 ± 4.0 24.7 ± 5.3 0.016
Albuminemia < 35 g/l 331/108 52 (16) 28 (26) 24 (11) < 0.001
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relevant and the full-text copies were obtained. Of these
articles, 44 studies, including our cohort, were included
in the meta-analysis (Fig. 2). Eighteen articles were in-
cluded in the SMR analysis, representing a total popula-
tion of 11,719 patients [7–12, 15, 22–24, 26, 33–38].
Thirty-six studies were included in the prognosis factor
analysis, representing a total of 26,187 patients [3, 7, 10–
18, 20, 22–26, 34, 39–55]. No study was excluded based
on poor quality. The main characteristics of the studies are
summarized in Additional file 1: Table S2 and Table S3.
SMR meta-analysis
The pooled SMR for all studies was 3.45 (95% CI 3.03–
3.94; I2 = 88.8%; p(het) < 0.001). The pooled SMR for
studies including only incident patients was 3.64 (95%
CI 3.06–4.34; I2 = 82.0%; p(het) < 0.001), and the pooled
SMR for studies including prevalent patients was 3.28
(95% CI 2.69–3.99; I2 = 91.6%; p(het) < 0.001). There was
no funnel plot asymmetry, and Egger’s test failed to pro-
vide any evidence for small study effect, making publica-
tion bias unlikely. Meta-regression stratified by study
type (incident or prevalent) did not show any association
with SMR (p = 0.461), meaning no statistical difference
between pooled SMR of incident and prevalent studies.
Subsequent analyses were therefore conducted on all
Table 1 Demographics and clinical characteristics of 625 patients with SSc at baseline (Continued)
N (N for dcSSc) Total dcSSc lcSSc p
Muscular involvement 604/172 137 (23) 71 (41) 66 (15) < 0.001
CPK > 200 IU/l 250/82 66 (26) 33 (40) 33 (20) < 0.001
Joint involvement 598/172 291 (49) 127 (74) 164 (39) < 0.001
Cancer 625/179 49 (8) 17 (10) 32 (7) 0.327
Hemoglobin 559/163 13.0 ± 1.6 12.5 ± 1.6 13.1 ± 1.5 < 0.001
Anemia 559/163 127 (23) 52 (32) 75 (19) 0.001
CRP > 8mg/l 470/136 118 (25) 57 (42) 61 (18) < 0.001
Serologic features
ACA 557/151 221 (40) 6 (4) 215 (53) < 0.001
Anti-Scl70 antibodies 504/149 177 (35) 90 (60) 87 (25) < 0.001
Anti-U1RNP antibodies 342/63 15 (4) 4 (6) 11 (4) 0.492
Anti-RNAP3 antibodies 345/72 18 (5) 13 (18) 5 (2) < 0.001
Anti-PMScl antibodies 343/62 16 (5) 3 (5) 13 (5) 1.000
Anti-SSa antibodies 387/79 60 (16) 20 (25) 40 (13) 0.014
Anti-SSb antibodies 338/62 11 (3) 3 (5) 8 (3) 0.431
APL antibodies 441/129 31 (7) 16 (12) 15 (5) 0.007
Low complement 482/130 18 (4) 6 (5) 12 (3) 0.589
Smoking 572/158 215 (38) 69 (44) 146 (35) 0.067
Results are expressed as n (%) for qualitative variables and mean ± SD or median [IQR] for quantitative variables
N number of patients with available data, lcSSc limited cutaneous systemic sclerosis, mRSS modified Rodnan score, GFR glomerular filtration rate,
AV block atrioventricular block, BB block bundle branch block, LVEF left ventricular ejection fraction, PH pulmonary hypertension, PAH pulmonary
arterial hypertension, echo echocardiography, RHC right heart catheterization, 6MWD 6-min walking distance, sPAP systolic pulmonary arterial
pressure, TLC total lung capacity, FVC forced vital capacity, DLCO diffusing capacity of the lungs for carbon monoxide, CRP C reactive protein,
BMI body mass index, ACA anti-centromere antibodies, APL antiphospholipid antibodies
Fig. 1 Kaplan-Meier survival curves from diagnosis for lcSSc and
dcSSc patients in the French cohort
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Table 2 Prognosis factors: non-adjusted and adjusted analysis on age at diagnosis, sex, and SSc subtype in the French cohort
Non-adjusted HR p Adjusted HR p
Demographics
Male sex 2.00 (1.31–3.05) 0.001 1.53 (0.98–2.39) 0.060
Age at diagnosis (per 1 year) 1.05 (1.04–1.07) < 0.001 1.08 (1.04–1.12) < 0.001
Age at diagnostic > 60 years 4.97 (2.53–9.78) < 0.001 5.79 (2.92–11.49) < 0.001
Disease duration at time of diagnosis (per 1 year) 1.02 (0.97–1.07) 0.542 1.01 (0.96–1.06) 0.763
African origin (vs. European) 0.79 (0.38–1.62) 0.516 0.93 (0.43–2.03) 0.864
Skin involvement
dcSSc subtype (vs. lcSSc) 2.06 (1.39–3.05) < 0.001 2.40 (1.58–3.64) < 0.001
mRSS > 5 1.24 (1.12–1.38) < 0.001 1.21 (1.03–1.43) 0.022
Past and/or active digital ulcers 1.22 (0.79–1.90) 0.371 1.29 (0.81–2.04) 0.277
Telangiectasia 1.64 (1.08–2.48) 0.019 1.55 (1.02–2.35) 0.039
Calcinosis 1.37 (0.79–2.36) 0.260 1.22 (0.69–2.16) 0.503
Lung involvement
NYHA class I – –
NYHA class II 2.68 (1.46–4.92) 0.001 2.37 (1.29–4.36) 0.006
NYHA class III 17.53 (3.97–14.27) < 0.001 6.74 (3.53–12.88) < 0.001
NYHA class IV 25.76 (10.55–62.92) < 0.001 16.61 (6.68–41.26) < 0.001
NYHA classes III–IV (vs. class I) 4.68 (3.07–7.13) < 0.001 4.33 (2.82–6.66) < 0.001
6MWD (per 100 m) 0.46 (0.36–0.58) < 0.001 0.51 (0.39–0.67) < 0.001
TLC < 70% predicted 3.87 (2.36–6.35) < 0.001 3.38 (1.96–5.82) < 0.001
FVC < 70% predicted 3.11 (1.92–5.02) < 0.001 2.79 (1.62–4.80) < 0.001
DLCO < 70% predicted 4.01 (2.33–6.89) < 0.001 3.31 (1.87–5.88) < 0.001
Interstitial lung disease 1.99 (1.32–2.99) < 0.001 1.50 (0.96–2.34) 0.072
PH (echo. and/or RHC) 5.01 (3.18–7.89) < 0.001 4.15 (2.59–6.65) < 0.001
sPAP < 35 mmHg – –
35–46 mmHg 2.05 (0.98–4.28) 0.056 1.26 (0.58–2.70) 0.559
> 46 mmHg 6.44 (3.69–11.22) < 0.001 5.94 (3.30–10.72) < 0.001
PAH (RHC) 4.96 (2.82–8.72) < 0.001 4.39 (2.43–7.93) < 0.001
Heart involvement
Arrhythmia 2.44 (0.98–6.02) 0.054 1.31 (0.52–3.32) 0.569
AV block 0.95 (0.13–6.80) 0.956 1.15 (0.15–8.58) 0.890
BB block 1.26 (0.31–5.15) 0.748 1.37 (0.33–5.67) 0.661
LVEF < 50% 1.82 (0.25–13.24) 0.555 0.92 (0.12–6.84) 0.938
Diastolic dysfunction 1.36 (0.43–4.35) 0.603 0.97 (0.30–3.13) 0.953
Pericarditis 1.74 (0.84–3.61) 0.139 1.07 (0.50–2.26) 0.864
Valvular disease 4.03 (1.97–8.25) < 0.001 2.20 (1.05–4.60) 0.037
Renal involvement
Scleroderma renal crisis 3.44 (2.01–5.89) < 0.001 2.95 (1.61–5.40) < 0.001
GFR < 80 ml/min 1.64 (1.06–2.52) 0.025 1.37 (0.85–2.21) 0.199
Gastrointestinal involvement 1.07 (0.68–1.69) 0.756 1.02 (0.65–1.62) 0.916
BMI < 18.5 kg/m2 1.10 (0.45–2.74) 0.831 1.79 (0.71–4.51) 0.220
Albuminemia < 35 g/l 2.30 (1.24–4.30) 0.009 1.45 (0.75–2.82) 0.270
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Table 2 Prognosis factors: non-adjusted and adjusted analysis on age at diagnosis, sex, and SSc subtype in the French cohort
(Continued)
Non-adjusted HR p Adjusted HR p
Muscular involvement 1.66 (1.10–2.51) 0.016 1.46 (0.92–2.31) 0.106
CPK > 200 IU/L 1.27 (0.58–2.76) 0.550 1.15 (0.50–2.64) 0.740
Joint involvement 1.22 (0.82–1.80) 0.329 1.08 (0.70–1.66) 0.720
Cancer 2.44 (1.41–4.21) 0.001 1.86 (1.07–3.26) 0.029
Anemia 2.66 (1.75–4.06) < 0.001 2.37 (1.54–3.66) < 0.001
CRP > 8mg/l 2.05 (1.28–3.27) 0.003 1.70 (1.02–2.82) 0.041
Serologic features
ACA 0.95 (0.62–1.44) 0.795 0.85 (0.55–1.31) 0.459
Anti-Scl70 antibodies 0.87 (0.55–1.36) 0.534 0.82 (0.51–1.30) 0.390
Anti-U1RNP antibodies 1.41 (0.51–3.93) 0.506 1.32 (0.44–3.92) 0.616
Anti-RNAP3 antibodies 0.96 (0.23–3.94) 0.949 1.32 (0.44–3.92) 0.616
Anti-PMScl antibodies 0.33 (0.05–2.41) 0.277 0.49 (0.07–3.54) 0.476
APL antibodies 1.54 (0.71–3.35) 0.280 1.18 (0.53–2.63) 0.679
Low complement 2.40 (0.97–5.95) 0.059 2.38 (0.95–5.95) 0.063
Smoking 1.06 (0.69–1.62) 0.795 0.97 (0.59–1.59) 0.901
Results are expressed as hazard ratios and 95% confidence interval
lcSSc limited cutaneous systemic sclerosis, dcSSc diffuse cutaneous systemic sclerosis, mRSS modified Rodnan score, GFR glomerular filtration rate,
AV block atrioventricular block, BB block bundle branch block, LVEF left ventricular ejection fraction, PH pulmonary hypertension, PAH pulmonary
arterial hypertension, echo echocardiography, RHC right heart catheterization, 6MWD 6-min walking distance, sPAP systolic pulmonary arterial
pressure, HRCT high-resolution computer tomography, TLC total lung capacity, FVC forced vital capacity, DLCO diffusing capacity of the lungs for
carbon monoxide, CRP C reactive protein, BMI body mass index, ACA anti-centromere antibodies, APL antiphospholipid antibodies
Fig. 2 Flow chart showing search strategy to identify studies in the meta-analysis
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studies. Meta-regression analysis revealed a significant
increase of SMR with proportion of dcSSc (p < 0.001)
and prevalence of anti-Scl70 antibodies (p = 0.021).
There was no association with male sex (p = 0.130).
There was no significant association between SMR and
mid-cohort year (p = 0.656) (Additional file 2: Figure S1.
Prognosis factors meta-analysis).
Prognosis factor meta-analysis
Table 3 shows the results of the meta-analysis of prognosis
factors. Age at disease onset, age at diagnosis, male sex,
African origin, dcSSc, anti-Scl70 antibodies, renal involve-
ment, scleroderma renal crisis, ILD, cardiac involvement,
PH, and cancer were significantly associated with a worse
prognosis. The presence of PH, diagnosed by Doppler
echocardiography and/or RHC, was associated with a poor
outcome (pooled HR = 3.44; 95% CI 2.59–4.58; I2 = 61.5%;
p(het) = 0.002). Meta-analysis of the five studies with PH
defined by RHC revealed a pooled HR of 5.27 (95% CI
2.98–9.31; I2 = 63.7%; p(het) = 0.027) for mortality. Het-
erogeneity could not be fully explained by the use of either
echocardiography or RHC alone in defining PH as re-
vealed by meta-regression stratified by the PH diagnosis
method (p for residual heterogeneity = 0.012). The pres-
ence of ACA was associated with a better survival, while
the presence of joint involvement was not associated with
prognosis (Additional file 2: Figure S2).
Discussion
The main results of our study are (i) a high risk of mortal-
ity in our cohort of incident patients, as shown by a high
SMR of 5.73; (ii) the identification of age > 60 years, dcSSc,
dyspnea, PH, low FVC, low DLCO, kidney involvement,
valvular disease, cancer, telangiectasia, shorter 6MWD,
anemia, and inflammation as prognosis factors in our co-
hort; (iii) a high pooled SMR of 3.45 in the meta-analysis
of the literature, including our new cohort; and (iv) the
additional identification of male sex, African origin, ILD,
cardiac involvement, and anti-Scl-70 antibodies as associ-
ated with worse prognosis in our meta-analysis, while
ACA were associated with better prognosis.
Survival and SMR
With a mid-cohort year of 2008, our study population is
the largest multicenter incident and well-phenotyped co-
hort study of SSc patients in France and is among the
most recent published to date in the literature. The overall
survival rates at 5 and 10 years from diagnosis were 85.9%
and 71.7%, respectively, and are lower than those reported
in other recent cohorts [7, 22, 24, 44, 54]. We also report
one of the highest SMR of 5.73. These differences could
be explained by a high heterogeneity between studies as
well as methodological issues such as the inclusion of
prevalent cases in many studies or differences in time ori-
gin from which survival time is calculated (from disease
onset, diagnosis, or enrolment). It is usually admitted that
Table 3 Results of the meta-analysis of prognosis factors in SSc
Number of cohorts HR 95% CI I2 (%) p(het) Egger’s test
Age at disease onset (per 1 year) 6 1.05 (1.04–1.07) 68.6 0.007 0.783
Age at diagnosis (per 1 year) 5 1.04 (1.04–1.05) 71.2 0.008 0.025
Male sex 21 1.87 (1.61–2.18) 50.9 0.004 < 0.001
African origin 5 1.38 (1.15–1.66) 25.0 0.255 0.774
dcSSc 23 1.90 (1.62–2.23) 58.3 < 0.001 < 0.001
Anti-Scl70 autoantibodies 13 1.38 (1.09–1.74) 49.6 0.022 0.024
ACA 8 0.62 (0.47–0.82) 56.4 0.025 0.590
Joint involvement 4 1.32 (0.82–2.12) 54.0 0.089 0.508
Renal involvement 9 2.79 (1.95–3.99) 50.9 0.039 0.512
Scleroderma renal crisis 10 3.89 (2.38–6.36) 75.6 < 0.001 0.097
ILD 14 2.34 (1.78–3.08) 69.5 < 0.001 < 0.001
Cardiac involvement 7 4.35 (2.28–8.29) 89.9 < 0.001 0.077
PH (echocardiography
or RHC)
13 3.44 (2.59–4.58) 61.5 0.002 0.057
PH (RHC) 5 5.27 (2.98–9.31) 63.7 0.027 0.761
Cancer 6 2.11 (1.27–3.50) 76.2 < 0.001 0.016
Results are expressed as hazard ratios with 95% confidence interval. The I2 statistics describes the percentage of variation across studies that is due to
heterogeneity rather than chance. p(het) is the p value for the 2 test for heterogeneity. Egger’s test checks for funnel plot asymmetry
dcSSc diffuse cutaneous systemic sclerosis, ILD interstitial lung disease, ACA anti-centromere antibodies, PH pulmonary hypertension, RHC right
heart catheterization
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studies including prevalent cases underestimate mortality
and that better survival is observed in prevalent patients
with longer disease duration prior to inclusion. Yet, our
meta-analysis did not show a significant difference be-
tween pooled SMR of studies that included prevalent
cases and those restricted to incident according to the au-
thors’ definition. The high heterogeneity observed within
studies with incident patients could be due to the defin-
ition of incidence and the proportion of males and
patients with anti-Scl70 antibodies. This high heterogen-
eity could explain the lack of difference between incident
and prevalent cohorts. Meta-regression showed a
significant association between SMR and proportion of
dcSSc (p < 0.001) and prevalence of anti-Scl70 antibodies
(p = 0.021). Our high SMR of 5.73 could therefore be
partly explained by the high proportion of anti-Scl70 anti-
bodies (35%) in our population. Interestingly, there has
been a debate whether or not the survival could have im-
proved over time in SSc. Our study did not show any im-
provement of SMR over time, which is in line with the
study of Elhai et al. [6]. However, considering life expect-
ancy in OECD (Organisation for Economic Co-operation
and Development) countries increased by 12 years from
1960 to 2014 [56], and SMR being the ratio of mortality in
SSc cohorts to that of the general population, this suggests
that all-cause mortality has decreased proportionately to
the general population in SSc cohorts.
Prognosis factors
Prognosis factors have been assessed in many obser-
vational studies [7, 13–26] and have been recently
reviewed. Our systematic review and meta-analysis, as
well as two prior meta-analyses [5, 27] and a recent
EUSTAR study [2], have identified the following char-
acteristics as consistently associated with a worse
prognosis: male gender; older age; dcSSc; lung and
cardiac involvement, including PH and ILD; kidney
involvement; and inflammation. These robust factors
are included in a recent prognosis score [2] as well as
in older ones [57, 58].
Besides these well-known prognosis factors, our cohort
study identifies new ones: telangiectasia, 6MWD, valvular
disease, cancer, and autoantibody status.
Telangiectasia was slightly associated with a higher mor-
tality in our study population. In contrast, Poormoghim et
al. [51] reported a non-significant, yet elevated HR of 1.44
in a smaller cohort of Iranian patients. An increased num-
ber of telangiectasia has been suggested to be a clinical
marker of microvascular disease in SSc and is associated
with an increased risk of PAH [59].
The 6MWD is a simple tool used to assess submaxi-
mal functional capacity. It is influenced by various dis-
ease parameters during SSc and lacks organ specificity
[60]. While the 6MWD has been shown to be an
independent predictor of mortality in idiopathic PAH, its
prognosis value in SSc-PAH is less clear [61]. To our
knowledge, we are the first to report a negative associ-
ation of the 6MWD with survival (HR = 0.51) in SSc pa-
tients. This can be at least partly explained by the
association between the 6MWD and PAH [60].
While cardiac involvement in SSc patients is robustly
associated with a poor prognosis, conferring a nearly
fivefold increased risk of mortality in our meta-analysis,
no study had yet focused on the valvular manifestations
of SSc. A recent article comparing echocardiography in
SSc patients and a matched control population showed a
greater frequency of valvular regurgitation and valvular
replacement due to regurgitation [62]. Moreover, in a
large multicenter French cohort, De Groote et al. [63]
reported 6.7% mitral regurgitation and 2.5% aortic regur-
gitations. To our knowledge, we are the first to describe
an association between valvular disease and survival in
SSc. These data indicate that more attention should be
paid to valvular disease in SSc patients and further stud-
ies are needed to confirm its prognostic significance.
An increased incidence of malignancy has been re-
ported during SSc, especially lung and hematological
cancer [64]. Cancer has also been described among the
leading cause of non-SSc-related deaths [7, 11, 15, 65],
and a temporal relation has been reported between the
onset of cancer and SSc [66]. As expected, in our cohort
as well as in the meta-analysis, malignancy was signifi-
cantly associated with shorter survival.
In our cohort, we did not observe any association be-
tween anti-Scl70 antibodies or ACA and survival. Inter-
estingly, the absence of association of anti-Scl70
antibodies with survival has been suggested by numer-
ous studies [7, 17, 18, 23, 25] while the protective role of
anti-centromere antibodies is better established [7, 18,
22, 25, 48]. Our meta-analysis confirms that the pres-
ence of ACA is associated with better survival (pooled
HR = 0.58). Moreover, our meta-analysis suggests that
the presence of anti-Scl70 antibodies could be indeed a
predictor of mortality with a pooled HR of 1.38. Our
analysis also highlights a probable publication bias. Small
studies reporting a negative association of anti-Scl70
antibodies with death are notably lacking. Therefore, it
is difficult to draw a firm conclusion on the role of
anti-Scl70 antibodies as a prognosis factor in SSc.
The major strength of our study is the availability of de-
tailed clinical and laboratory characteristics in a multicen-
ter cohort of incident patients. The major strengths of our
meta-analysis include (i) the first analysis of pooled HR of
anti-Scl70/ACA antibodies, (ii) the separate analysis of
pooled SMR in incident cohorts of SSc, and (iii) the separ-
ate analysis of pooled HR of PH diagnosed by RHC only.
The main limitation is a proportion of loss to
follow-up of around 20% in our cohort, despite our
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attempts to collect information on participants who
dropped out. These patients lost to follow-up had a
higher prevalence of ILD and lower prevalence of ACA
at baseline, leading to potential underestimation of mor-
tality. A second limitation is the variable definition of in-
cident patients among studies. Although we defined
incident patients as newly diagnosed ones, these patients
had relatively short disease duration from first non-RP
symptom diagnosis, thus minimizing survivor bias. Be-
cause of missing values, the effect of specific treatments
and other data such as type and stage of cancer could
not be studied, and no multivariate analysis could be
performed. In addition, multiple univariate tests are re-
sponsible for an inflation of the alpha risk. However,
multiple test adjustments in such exploratory study, in
addition for a rare disease, are not strictly required [67].
Finally, our study was performed in five selected referral
centers and may therefore have focused on a subset of
patients with more severe disease, which could limit the
representativeness of our findings.
Conclusions
Our results show that mortality is still high in SSc.
Strong prognosis factors identified at baseline are age at
diagnosis > 60 years, dcSSc subtype, scleroderma renal
crisis, severe dyspnea, FVC and DLCO < 70%, PH,
anemia, and CRP > 8mg/l. Our study also suggests the
prognosis value of telangiectasia, 6MWD, valvular dis-
ease, cancer, and autoantibody status.
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